Literature DB >> 26822567

Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins.

Elena Gazzano1, Konstantin Chegaev2, Barbara Rolando2, Marco Blangetti2, Lorenzo Annaratone2, Dario Ghigo1, Roberta Fruttero2, Chiara Riganti3.   

Abstract

A library of nitric oxide-donor doxorubicins (NO-DOXOs) was synthesized by linking appropriate NO-donor moieties at C-14 position through an ester bridge. Their hydrolytic stability was evaluated. The intracellular accumulation and cytotoxicity of these novel NO-DOXOs were studied in DOXO-sensitive (HT29) and DOXO-resistant (HT29/dx) tumor-cells. Hydrolytically-stable compounds accumulated in HT29 and HT29/dx cells, thanks to the nitration of plasma-membrane efflux transporters. Surprisingly, no close correlation was found between intracellular accumulation and cytotoxicity. Only compounds with high mitochondria retention (due to nitration of mitochondrial efflux transporter) exert high cytotoxicity, through the activation of a mitochondrial-dependent apoptosis.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Doxorubicin; Mitochondria; Multidrug resistance; Nitric oxide

Mesh:

Substances:

Year:  2016        PMID: 26822567     DOI: 10.1016/j.bmc.2016.01.021

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

1.  Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance.

Authors:  Konstantin Chegaev; Aurore Fraix; Elena Gazzano; Gamal Eldein F Abd-Ellatef; Marco Blangetti; Barbara Rolando; Sabrina Conoci; Chiara Riganti; Roberta Fruttero; Alberto Gasco; Salvatore Sortino
Journal:  ACS Med Chem Lett       Date:  2017-01-30       Impact factor: 4.345

2.  New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations.

Authors:  Elisabetta Bigagli; Cristina Luceri; Maria De Angioletti; Konstantin Chegaev; Mario D'Ambrosio; Chiara Riganti; Elena Gazzano; Simona Saponara; Mariangela Longini; Francesca Luceri; Lorenzo Cinci
Journal:  Invest New Drugs       Date:  2018-04-02       Impact factor: 3.850

3.  Elimination of stem-like cancer cell side-population by auranofin through modulation of ROS and glycolysis.

Authors:  Guo-Xin Hou; Pan-Pan Liu; Shengyi Zhang; Mengqi Yang; Jianwei Liao; Jing Yang; Yumin Hu; Wen-Qi Jiang; Shijun Wen; Peng Huang
Journal:  Cell Death Dis       Date:  2018-01-24       Impact factor: 8.469

4.  Doxorubicin-NO Releaser Molecular Hybrid Activatable by Green Light to Overcome Resistance in Breast Cancer Cells.

Authors:  Cristina Parisi; Francesca Moret; Aurore Fraix; Luca Menilli; Mariacristina Failla; Federica Sodano; Claudia Conte; Fabiana Quaglia; Elena Reddi; Salvatore Sortino
Journal:  ACS Omega       Date:  2022-02-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.